NEOLEUKIN THERAPEUTICS
Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. They are creating next generation immunotherapies using breakthrough de novo protein design technology. They use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.
NEOLEUKIN THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical
Founded:
2003-12-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.neoleukin.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
157.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics Apache
Similar Organizations
Genocea Biosciences
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies.
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Current Employees Featured
Founder
Investors List
Sahsen Ventures
Sahsen Ventures investment in Venture Round - Neoleukin Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-09 | Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research |
Official Site Inspections
http://www.neoleukin.com Semrush global rank: 9.37 M Semrush visits lastest month: 169
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 15.197.148.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Neoleukin Therapeutics"
Neoleukin Therapeutics - Crunchbase Company Profile …
Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. They are creating next generation immunotherapies using breakthrough de novo protein design technology.See details»
Neoleukin - Org Chart, Teams, Culture & Jobs - The Org
View Neoleukin's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Seattle-based Neoleukin Folded into New York Biotech …
Jan 9, 2024 · Neoleukin Therapeutics, a biotech company that spun out of the University of Washington in 2019, finalized its merger with Neurogene, a biotech firm based in New York on December 19. Neurogene will pass its name down …See details»
Neurogene Announces Closing of Merger with …
NEW YORK, December 19, 2023 -- (BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE) ("Neurogene"), a clinical-stage company founded to bring life-changing genetic medicines to patients and families...See details»
Neurogene and Neoleukin Announce Definitive Merger Agreement
Jul 18, 2023 · Neoleukin Therapeutics, Inc. Proposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene’s differentiated portfolio of genetic medicines for …See details»
Neoleukin: from spinout to public company in 7 months
Aug 8, 2019 · The combined company will change its name to Neoleukin Therapeutics, and will continue to advance its Rosetta-designed protein platform for cancer, inflammation, and autoimmune diseases. Neoleukin was spun out …See details»
www.neoleukin.com
Www.neoleukin.comSee details»
A zwitterionic twist | Nature Reviews Chemistry
Sep 23, 2024 · These results propelled the research team to investigate their EKP fusion strategy with another therapeutic protein, Neoleukin-2/15 cytokine (Neo). Neo is a potent cancer …See details»
Neoleukin Therapeutics Provides Strategic Update and Announces ...
Mar 8, 2023 · Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design …See details»
Aquinox Pharmaceuticals and Neoleukin Therapeutics announce …
Aug 6, 2019 · Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. For more information, please visit the Neoleukin …See details»
Neurogene concludes merger deal with Neoleukin …
Dec 20, 2023 · Neurogene has concluded its merger deal with biopharmaceutical company Neoleukin Therapeutics to become a combined company focusing on the development of differentiated genetic therapies for complex neurological …See details»
Lewis Williams - Board Member at Neoleukin - The Org
Dr. Williams is co-founder, Chairman and CEO of Walking Fish Therapeutics, a private early stage cell therapy company, and is a venture partner of Quan Capital, LLC. Prior to Walking Fish, Dr …See details»
Neurogene Announces Closing of Merger with Neoleukin …
Dec 19, 2023 · NGN-401 is an investigational adeno-associated virus (AAV9) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize therapeutic …See details»
Neurogene inks Neoleukin reverse merger to fund gene therapies
Jul 18, 2023 · Neurogene has struck deals to fund its pipeline of gene therapies into the second half of 2026, agreeing to merge with the floundering, Nasdaq-listed Neoleukin Therapeutics …See details»
NL-201, a De Novo Agonist of IL-2 and IL-15 Receptors, …
Nov 5, 2021 · NL-201 is a potent, selective, and long-acting computationally designed alpha-independent agonist of the IL-2 and IL-15 receptors that is being developed as an …See details»
A split, conditionally active mimetic of IL-2 reduces the ... - Nature
Oct 31, 2022 · We demonstrate the approach with a previously designed mimetic of cytokines interleukin-2 and interleukin-15—Neoleukin-2/15 (Neo-2/15)—both for trans -activating …See details»
Restoring IL-2 to its cancer immunotherapy glory - Nature
Feb 18, 2021 · The FDA approved a recombinant IL-2 called aldesleukin, at the time owned by Chiron Corporation, for metastatic renal cancer in 1992 and for metastatic melanoma in 1998. …See details»
Shares of Neoleukin Therapeutics spike after announcing
Mar 9, 2023 · Neoleukin Therapeutics is slashing its workforce by about 70% as it seeks “strategic alternatives” for its future, according to a company statement Wednesday. The publicly traded …See details»
Neoleukin: New Phase 1 Initiation, Strong Managerial Expertise, …
Dec 18, 2020 · Neoleukin Therapeutics is a biopharmaceutical company that creates next-gen immunotherapies targeting cancer, inflammation, and autoimmunity. Neoleukin's unique value …See details»
Neoleukin-2 enhances anti-tumour immunity downstream of …
Here, we developed a platform for testing potential CD8 T cell tumour vaccine candidates. We used a high-affinity alpaca-derived VHH against MHC class II to deliver peptides to …See details»